

Fluid Therapy

Adesola Odunayo, DVM, MS, DACVECC
University of Tennessee




Fluid therapy is an essential therapeutic component in small animal practice. Normal cellular function can be impaired without water and potentially lead to patient death.¹ Intravenous fluids may be prescribed to hospitalized patients to treat hypovolemia, dehydration, electrolyte imbalance, and acid-base abnormalities and to ensure that adequate cellular maintenance requirements are met.²

Fluid Compartments

Understanding the concept of fluid compartments can help the clinician determine the location of the fluid deficit and appropriate treatment. The body weight of nonobese cats and dogs is com-

posed of approximately 60% water.² Puppies and kittens have higher total body water amount (ie, up to 80% of body weight), as total body water decreases with age.³ In addition, fat has a lower water content; thus, the fluid prescription should be based on estimated lean body weight.⁴ In adult nonobese cats and dogs, approximately two-thirds of total body water (ie, 66% of total body water or ≈40% of body weight) is in the intracellular space. The remaining one-third (ie, 33% of total body water or ≈20% of body weight) is in the extracellular space; of this extracellular body water, 75% (≈15% of body weight) is in the interstitial space and 25% (≈5% of body weight) is in the intravascular space (*Figure*, next page). Intracellular fluid loss is generally not appreciated on physical examination and typically manifests as hypernatremia. Treatment of intracellular fluid deficit is beyond the scope of this article.



▲ FIGURE Distribution of total body water in an adult nonobese cat or dog

TABLE 1

PHYSICAL & LABORATORY ABNORMALITIES IN PATIENTS WITH HYPOVOLEMIA & DEHYDRATION

Hypovolemia	Dehydration
Tachycardia (bradycardia in terminal stages) in dogs	Dry mucous membranes
Pale mucous membranes	Doughy abdomen
Weak peripheral pulses	Sunken eyes
Altered mentation	Skin tenting
Prolonged capillary refill time	Azotemia
Cold extremities	Elevated hematocrit and total protein
Hypotension	
Elevated lactate	
Hypothermia, bradycardia (heart rate, <160 bpm), and hypotension*	

* Cats tend to demonstrate this triad.

Intravascular fluid deficit (ie, hypovolemia) leads to inadequate oxygen delivery to the cells (ie, poor perfusion or shock). Untreated intravascular fluid deficit can be life-threatening, as oxygen is important for minute-to-minute cellular function maintenance. Inadequate oxygen delivery can lead to hyperlactatemia through anaerobic glycolysis, cell membrane disruption, cell death, and organ death.⁵ Physical examination findings of hypovolemia (**Table 1**) include tachycardia in dogs, bradycardia in cats (and in the terminal stages of shock in dogs), prolonged capillary refill time, pale mucous membranes, weak peripheral pulses, cold extremities, and altered mental state. Patients exhibiting these signs require emergent treatment to rapidly restore oxygen delivery. Common clinical conditions that lead to intravascular fluid loss include hemorrhage secondary to trauma, coagulopathy, neoplasia, gastroenteritis, pancreatitis, and peritonitis.

Interstitial fluid deficit (ie, dehydration) is commonly assessed based on a percentage of the estimated interstitial fluid lost (**Table 2**) and typically does not result in life-threatening abnormalities unless dehydration progresses to approximately 9% or greater. Signs of dehydration that may be identified on physical examination include skin tenting, dry mucous membranes, doughy abdomen, and sunken eyes. The different clinical approaches and urgency for treating poor perfusion and dehydration make differentiating between them vital (**Table 1**).

Fluid Types

A crystalloid is a water-based solution composed of osmotically active small molecules that are permeable to the capillary.⁶ A significant percentage of crystalloids move into the interstitial and intracellular space within approximately 45 minutes of intravenous administration. Isotonic crystalloids (eg, 0.9% NaCl, lactated Ringer’s solution), which are primarily used for fluid therapy in veteri-

nary medicine, have osmolality similar to plasma and therefore do not cause cellular swelling or shrinkage when administered.⁶ Hypotonic and hypertonic crystalloids have lower and higher osmolality, respectively, as compared with plasma.

Synthetic colloids (eg, hydroxyethyl starch solutions) are colloid-based fluids composed of large molecules that do not cross the capillary membrane. Colloids can be used to treat hypovolemia and/or hypoproteinemia.⁷⁻⁹ Synthetic colloids should be used cautiously in veterinary patients^{10,11} because of concerns in human patients that acute kidney disease and coagulopathies may develop.

Fluid Prescription

A quick stepwise approach that provides an individualized fluid plan for the patient is needed once it has been determined that fluid therapy may be beneficial. Using a fluid prescription consisting of 3 straightforward steps (vs arbitrarily putting a patient on a 2× maintenance fluid rate) ensures that the patient's fluid deficit is identified and corrected in a timely manner (see *Examples of Individualized Fluid Plans*, page 75). Ongoing fluid losses are not included in this plan but should be replaced in patients with significant ongoing fluid loss (eg, a puppy with parvoviral enteritis with continued vomiting and diarrhea).

Hypovolemia and dehydration can occur independently of each other; therefore, dehydrated patients may not be hypovolemic, and hypovolemic patients may not be dehydrated.

Step 1: Resuscitation (Identify & Treat Hypovolemia if Present)

Hypovolemia can lead to poor oxygen delivery and should be identified (*Table 1*) and treated quickly.¹² If hypovolemia is suspected or identified, fluids should be administered intravenously or via the intraosseous route.

TABLE 2

PHYSICAL EXAMINATION FINDINGS OF DEHYDRATION & ESTIMATE OF FLUID LOSS PERCENTAGE

Dehydration Percentage	Physical Examination Findings
<5%	Dehydration is not clinically detectable, but patient has history of fluid loss
5%-7%	Dry mucous membranes Skin tenting
7%-9%	Dry mucous membranes Skin tenting Sunken eyes Doughy abdomen
9%-12%	Dry mucous membranes Skin tenting Sunken eyes Doughy abdomen Evidence of hypovolemia may be present
12%-15%*	Dry mucous membranes Skin tenting Sunken eyes Doughy abdomen Evidence of hypovolemia is present

* Death is imminent.

Like any drug used in clinical medicine, fluids are not benign, and their use can potentially lead to life-threatening complications.

Fluids administered subcutaneously, in the peritoneal cavity, or through the oral route are not absorbed well because blood flow is diverted to the heart, lungs, and brain in a hypovolemic state. Cats with evidence of hypovolemia should be actively warmed to a body temperature of at least 97°F (36°C) before large volumes of fluids are given.

The shock dose is an estimate of the total blood volume (dogs, 90 mL/kg/hr; cats, 60 mL/kg/hr). It is unlikely that a hypovolemic patient will have lost its entire blood volume; thus, approximately 25% of the fluid prescription (dogs, 20 mL/kg/15 min; cats, 15 mL/kg/15 min¹³) should be administered using pressure bags, fluid pumps, or a 60-mL syringe. Fluid pumps run at 999 mL/hr and are best used for boluses when the total volume to be infused over 15 minutes is less than 250 mL.

The patient should be re-evaluated after the fluid bolus is given. Additional fluid boluses can be administered (dogs, ≤90 mL/kg/hr; cats, 60 mL/kg/hr) if clinical parameters of hypovolemia have improved but are not yet satisfactory (see *Oxygen Delivery Restoration Parameters*). Fluid administration

OXYGEN DELIVERY RESTORATION PARAMETERS

- ▶ Normal heart rate (dogs, 100-140 bpm; cats, >160 bpm)
- ▶ Pink mucous membranes
- ▶ Normal capillary refill time (<2 seconds)
- ▶ Normal peripheral pulses
- ▶ Improved mentation
- ▶ Improved blood pressure (100-140 mm Hg systolic)
- ▶ Improved serum lactate (1-2.5 mmol/L)

can be discontinued when the patient has met the desired criteria, but, because isotonic crystalloids have a short lifespan in the intravascular space, the patient's vital parameters should be monitored closely.

Synthetic colloids (eg, hydroxyethyl starch solutions; 1-5 mL/kg every 15 minutes) can be used to treat hypovolemia. The author prefers to use the low end of the dose range for cats, whereas dogs tend to tolerate the higher end.

Step 2: Rehydration (Identify & Treat Dehydration if Present)

After hypovolemia (if present) is treated, the patient should be evaluated (*Table 1*, page 72) and treated for dehydration as needed. The fluid deficit in the interstitial space can be determined by multiplying the patient's body weight by the estimated dehydration percentage (*Table 2*, previous page)¹:

$$\text{Fluid deficit (liters)} = \text{weight in kg} \times \% \text{ dehydration}$$

The fluid deficit is then replaced over a period of 6 to 24 hours¹ using any isotonic crystalloid. The author prefers to replenish the fluid deficit over 6 to 8 hours except in cats and in patients with underlying heart disease, in which the fluid deficit is replaced over 12 to 24 hours.

Step 3: Maintenance (Provide Cellular Maintenance Requirement)

Cells have a daily water requirement to maintain regular metabolism. Maintenance fluids (dogs, 60 mL/kg/q24h; cats, 45 mL/kg/q24h¹²) can be provided as part of the fluid plan when a patient is not eating or drinking, in addition to correcting dehydration and restoring perfusion. Multiple units of the maintenance dose (rates 2× or more above the maintenance rate) can be provided to patients that may benefit

Continues on page 76

from diuresis (eg, after exposure to toxins). Isotonic crystalloids are typically used to provide maintenance requirements, but hypotonic crystalloids (eg, 0.45% NaCl) may also be used.

Complications of Fluid Therapy

Like any drug used in clinical medicine, fluids are not benign, and their use can potentially lead to life-threatening complications, including respiratory distress secondary to volume overload, coagulopathies, electrolyte abnormalities, acid-base disturbances, and propagation of inflammation.¹⁴ Fluid prescriptions should be individualized and the patient monitored often to detect any adverse effects associated with fluid therapy. ■

References

- Mazzaferro E, Powell LL. Fluid therapy for the emergent small animal patient: crystalloids, colloids, and albumin products. *Vet Clin North Am Small Anim Pract.* 2013;43(4):721-734.
- Mensack S. Fluid therapy: options and rational administration. *Vet Clin North Am Small Anim Pract.* 2008;38(3):575-586.
- Macintire DK. Pediatric fluid therapy. *Vet Clin North Am Small Anim Pract.* 2008;38(3):621-627.
- Wellman ML, DiBartola SP, Kohn CW. Applied physiology of body fluids in dogs and cats. In: DiBartola SP, ed. *Fluid, Electrolyte, and Acid-Base Disorders in Small Animal Practice.* 4th ed. St. Louis, MO: WB Saunders; 2012:2-25.
- Pang DS, Boysen S. Lactate in veterinary critical care: pathophysiology and management. *J Am Anim Hosp Assoc.* 2007;43(5):270-279.
- Rudloff E, Kirby R. Fluid therapy. Crystalloids and colloids. *Vet Clin North Am Small Anim Pract.* 1998;28(2):297-328.
- Mandell DC, King LG. Fluid therapy in shock. *Vet Clin North Am Small Anim Pract.* 1998;28(3):623-644.
- Chan DL. Colloids: current recommendations. *Vet Clin North Am Small Anim Pract.* 2008;38(3):587-593.
- Kasper SM, Meinert P, Kampe S, et al. Large-dose hydroxyethyl starch 130/0.4 does not increase blood loss and transfusion requirements in coronary artery bypass surgery compared with hydroxyethyl starch 200/0.5 at recommended doses. *Anesthesiology.* 2003;99(1):42-47.
- Hayes G, Benedicenti L, Mathews K. Retrospective cohort study on the incidence of acute kidney injury and death following hydroxyethyl starch (HES 10% 250/0.5/5:1) administration in dogs (2007-2010). *J Vet Emerg Crit Care (San Antonio).* 2016;26(1):35-40.
- Reinhart K, Perner A, Sprung CL, et al. Consensus statement of the ESICM task force on colloid volume therapy in critically ill patients. *Intensive Care Med.* 2012;38(3):368-383.
- Brown AJ, Otto CM. Fluid therapy in vomiting and diarrhea. *Vet Clin North Am Small Anim Pract.* 2008;38(3):653-675.
- Davis H, Jensen T, Johnson A, et al. 2013 AAHA/AAFP fluid therapy guidelines for dogs and cats. *J Am Anim Hosp Assoc.* 2013;49(3):149-159.
- Mazzaferro EM. Complications of fluid therapy. *Vet Clin North Am Small Anim Pract.* 2008;38(3):607-619.

VETORYL® CAPSULES (trilostane)

5 mg, 10 mg, 30 mg, 60 mg and 120 mg strengths
Adrenocortical suppressant for oral use in dogs only.

BRIEF SUMMARY (For Full Prescribing Information, see package insert.)

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed veterinarian.

DESCRIPTION: VETORYL Capsules are an orally active synthetic steroid analogue that blocks production of hormones produced in the adrenal cortex of dogs.

INDICATION: VETORYL Capsules are indicated for the treatment of pituitary- and adrenal-dependent hyperadrenocorticism in dogs.

CONTRAINDICATIONS: The use of VETORYL Capsules is contraindicated in dogs that have demonstrated hypersensitivity to trilostane. Do not use VETORYL Capsules in animals with primary hepatic disease or renal insufficiency. Do not use in pregnant dogs. Studies conducted with trilostane in laboratory animals have shown teratogenic effects and early pregnancy loss.

WARNINGS: In case of overdosage, symptomatic treatment of hypoadrenocorticism with corticosteroids, mineralocorticoids and intravenous fluids may be required. Angiotensin converting enzyme (ACE) inhibitors should be used with caution with VETORYL Capsules, as both drugs have aldosterone-lowering effects which may be additive, impairing the patient's ability to maintain normal electrolytes, blood volume and renal perfusion. Potassium sparing diuretics (e.g. spironolactone) should not be used with VETORYL Capsules as both drugs have the potential to inhibit aldosterone, increasing the likelihood of hyperkalemia.

HUMAN WARNINGS: Keep out of reach of children. Not for human use. Wash hands after use. Do not empty capsule contents and do not attempt to divide the capsules. Do not handle the capsules if pregnant or if trying to conceive. Trilostane is associated with teratogenic effects and early pregnancy loss in laboratory animals. In the event of accidental ingestion/overdose, seek medical advice immediately and take the labeled container with you.

PRECAUTIONS: Hypoadrenocorticism can develop at any dose of VETORYL Capsules. A small percentage of dogs may develop corticosteroid withdrawal syndrome within 10 days of starting treatment. Mitotane (o,p'-DDD) treatment will reduce adrenal function. Experience in foreign markets suggests that when mitotane therapy is stopped, an interval of at least one month should elapse before the introduction of VETORYL Capsules. The use of VETORYL Capsules will not affect the adrenal tumor itself. Adrenalectomy should be considered as an option for cases that are good surgical candidates. The safe use of this drug has not been evaluated in lactating dogs and males intended for breeding.

ADVERSE REACTIONS: The most common adverse reactions reported are poor/reduced appetite, vomiting, lethargy/dullness, diarrhea, elevated liver enzymes, elevated potassium with or without decreased sodium, elevated BUN, decreased Na/K ratio, weakness, elevated creatinine, shaking, and renal insufficiency. Occasionally, more serious reactions, including severe depression, hemorrhagic diarrhea, collapse, hypoadrenocortical crisis or adrenal necrosis/rupture may occur, and may result in death.


VETORYL® CAPSULES
(trilostane)

Distributed by:
Dechra Veterinary Products
7015 College Boulevard, Suite 525
Overland Park, KS 66211

VETORYL is a trademark of
Dechra Ltd. © 2015, Dechra Ltd.

NADA 141-291, Approved by FDA


Dechra
Veterinary Products

EXAMPLES OF INDIVIDUALIZED FLUID PLANS

EXAMPLE 1

Gerald, a 4-year-old neutered male cat weighing 6.6 lb (3 kg), is presented for vomiting and diarrhea of 3 days' duration. He was anorexic and lethargic prior to presentation.

On physical examination, Gerald is quiet and has a heart rate of 120 bpm, pale mucous membranes with a capillary refill time of about 2 seconds, weak peripheral pulses, initial blood pressure of 50 mm Hg (systolic), and a body temperature of 94°F (34°C). He is also estimated to be about 6% dehydrated based on skin tenting and dry mucous membranes.

STEP 1: RESUSCITATION

Gerald has signs of hypovolemia (ie, bradycardia, hypotension, hypothermia, weak peripheral pulses, pale mucous membranes) and should be resuscitated immediately to restore oxygen delivery.

- ▶ A peripheral catheter—or intraosseous catheter if a peripheral catheter is difficult to place—should be used. The medial saphenous veins may be easier to access in hypovolemic cats.
- ▶ Exogenous heating (eg, forced air

warming devices) should be used to raise body temperature to at least 97°F (36°C).

- ▶ A 45-mL (15-mL/kg) balanced isotonic crystalloid (eg, lactated Ringer's solution, 0.9% NaCl) should be administered over 15 minutes using a 60-mL syringe or a fluid pump.
- ▶ Parameters should be reassessed and stopped if the patient has met the end goals (see *Oxygen Delivery Restoration Parameters*).
- ▶ As the patient's body temperature rises, additional fluid boluses can be given, if needed.

STEP 2: REHYDRATION

Gerald responded well to the fluid given during resuscitation. His heart rate is now 200 bpm, blood pressure is 100 mm Hg, and mucous membranes are pink. He still has signs of dehydration based on skin tenting and dry mucous membranes and is estimated at 6% dehydration. This fluid deficit should be replaced using an isotonic crystalloid.

- ▶ Fluid deficit calculation:
Fluid deficit (liters) =
weight in kg (3) × % dehydration (0.06)

Fluid deficit = 3 × 0.06

Fluid deficit = 0.18 L (180 mL)

- ▶ Timeframe needed to replace the fluid deficit (cats tend to be less fluid tolerant; Gerald's deficit will be replaced over 12 hours):
180 mL q12h = 15 mL/hr for 12 hours

STEP 3: MAINTENANCE

Hourly fluid requirements (ie, maintenance fluids) should be provided to maintain normal cellular activity. Because the patient is not eating or drinking, the maintenance requirement should be provided using an isotonic crystalloid; a hypotonic crystalloid can also be used to provide maintenance requirements.

- ▶ The maintenance fluid requirement is:
45 mL/kg q24h (45 × 3) = 135 mL/q24h or 6 mL/hr
- ▶ Overall fluid prescription after treating hypovolemia is:
Fluid deficit (15 mL/hr) + maintenance (6 mL/hr) = 21 mL/hr for the first 12 hours; fluid rate is then reduced to 6 mL/hr (provided there are no ongoing fluid losses)

EXAMPLE 2

Sasha, a 4-year-old female Dachshund weighing 15.4 lb (7 kg), is presented for evaluation after being hit by a car. Physical examination findings reveal a heart rate of 160 bpm, pale mucous membranes, a capillary refill time of 3 seconds, and weak peripheral pulses. She has a broken left femur and some abrasions associated with the fracture. The remainder of the findings are within normal limits.

STEP 1: RESUSCITATION

Sasha has signs of hypovolemia (ie, poor perfusion) based on tachycardia, prolonged capillary refill time, and weak peripheral pulses.

- ▶ A large-bore intravenous catheter should be placed and fluid therapy initiated to restore oxygen delivery. An analgesic—ideally opioids—should be administered for fracture-associated pain that may also lead to tachycardia.
- ▶ A 140-mL isotonic crystalloid bolus should be administered (20 mL/kg) rapidly over 15 minutes. A fluid pump may be used.
- ▶ Physical examination parameters should be reassessed to ensure end goals (see *Oxygen Delivery Restoration Parameters*) have been met after providing a fluid bolus. The crystalloid dose may be repeated up to 90 mL/kg/hr.

STEP 2: REHYDRATION

Physical examination findings consistent with dehydration are not found. This step can be skipped.

STEP 3: MAINTENANCE

Because Sasha is not likely to begin eating or drinking immediately, she will likely benefit from maintenance fluids.

- ▶ Maintenance fluid requirement is:
60 mL/kg q24h (60 × 7) = 420 mL q24h or 18 mL/hr
- ▶ Overall fluid prescription after treating hypovolemia is:
Fluid deficit (0 mL/hr) + maintenance (18 mL/hr) = 18 mL/hr until she starts to eat and drink on her own (provided there are no ongoing fluid losses)